Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is...

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones